Results 121 to 130 of about 15,946 (160)

Alterations in peripheral blood NK cell subsets and function in patients with HBeAg-positive chronic hepatitis B during pregnancy. [PDF]

Front Cell Infect Microbiol
Shen X, Zhang X, Cao Y, Zhang L, Yuan H, Wang H, Zhou Y, Diao S, Qi X, Li F, Fan Q, Li S.   +11 more
europepmc   +1 more source

Chronic hepatitis B in 2025: diagnosis, treatment and future directions. [PDF]

Clin Med (Lond)
Watson AG, Mulay AS, Gill US.
europepmc   +1 more source

Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study. [PDF]

Virol J
Zhang W, Chen J, Sun W, Xie N, Tian F, Zhang W, Ruan Q, Song J.   +7 more
europepmc   +1 more source

Early maternal tenofovir treatment and infant vaccination: a scalable model for hepatitis B virus mother-to-child transmission control in resource-limited areas. [PDF]

Transl Gastroenterol Hepatol
Islam MD, Coffin CS.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients

Journal of Gastroenterology and Hepatology, 2010
AbstractBackground and Aim:  To evaluate the usefulness of quantitative hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for predicting HBeAg seroconversion in chronic hepatitis B patients treated with conventional interferon (IFN) alfa‐2b or PegIFN alfa‐2b.Methods:  Fifty‐eight patients were enrolled; 29 for the training group and
Hui, Ma, Rui-Feng, Yang, Lai, Wei
openaire   +2 more sources

HBeAg in Viral Hepatitis Type B

Digestion, 1978
58 patients with acute hepatitis type B, including 13 with fulminant hepatitis, were tested on presentation for HBeAg. Positive results were obtained in 24%. The frequency was highest in those with fulminant hepatitis (46% positive), and this was probably related to the earlier presentation of patients with this condition. Patients with acute hepatitis
I L, Woolf, N, El Sheikh, H, Cullens, A L, Eddleston, R, Williams   +4 more
openaire   +2 more sources

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg‐positive chronic hepatitis B

Journal of Viral Hepatitis, 2011
Summary.  There are few reports on hepatitis B e antigen (HBeAg) titres during nucleos(t)ide analogues treatment. We investigated the changes in HBeAg levels in patients treated with entecavir and the usefulness of HBeAg quantification for predicting antiviral response.
J H, Kwon, J W, Jang, S, Lee, J, Lee, K W, Chung, Y S, Lee, J Y, Choi   +6 more
openaire   +2 more sources